Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 14.8%. This performance was worse than the S&P 500’s 8.5% decline.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including STERIS (NYSE:STE) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Zimmer Biomet (NYSE:ZBH) and the best and worst performers in the surgical equipment & consumables - diversified industry.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q4, starting with Solventum (NYSE:SOLV).
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including BD (NYSE:BDX) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at CONMED (NYSE:CNMD) and the best and worst performers in the surgical equipment & consumables - diversified industry.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.
This has weighed on the returns lately as the industry has pulled back by 1.7% over the past six months. This performance is a noticeable divergence from the S&P 500’s 9% return.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 1.7%. This drop is a stark contrast from the S&P 500’s 9% gain.
Medical equipment and services company Steris (NYSE:STE). fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 5.6% year on year to $1.37 billion. Its non-GAAP profit of $2.32 per share was in line with analysts’ consensus estimates.
